Climb Bio, Inc. (CLYM)

Market Cap	134.17M
Revenue (ttm)	n/a
Net Income (ttm)	-46.76M
Shares Out	67.76M
EPS (ttm)	-0.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,537,061
Open	2.040
Previous Close	2.040
Day's Range	1.950 - 2.120
52-Week Range	1.050 - 5.860
Beta	-0.06
Analysts	Strong Buy
Price Target	9.00 (+354.55%)
Earnings Date	Nov 11, 2025

About CLYM

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A n...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 10, 2021
• Employees: 18
• Stock Exchange: NASDAQ
• Ticker Symbol: CLYM
• Website: https://climbbio.com

Analyst Summary

According to 3 analysts, the average rating for CLYM stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 354.55% from the latest price.

Price Target

$9.0

(354.55% upside)

Analyst Consensus: Strong Buy